Clinical Trial Update: Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous/endometrial cancer completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Serous Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Yale University | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-04-18